Relay Therapeutics, Inc.
RLAY
$10.57
$0.434.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.00M | -- | 677.00K | 7.68M | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.00M | -- | 677.00K | 7.68M | 0.00 |
| Cost of Revenue | 56.34M | 67.89M | 61.47M | 73.81M | 64.43M |
| Gross Profit | -49.34M | -67.89M | -60.80M | -66.13M | -64.43M |
| SG&A Expenses | 13.59M | 12.50M | 13.75M | 18.74M | 20.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.93M | 80.39M | 75.22M | 92.55M | 84.98M |
| Operating Income | -62.93M | -80.39M | -74.55M | -84.87M | -84.98M |
| Income Before Tax | -54.89M | -74.15M | -70.38M | -77.07M | -76.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.89M | -74.15M | -70.38M | -77.07M | -76.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.89M | -74.15M | -70.38M | -77.07M | -76.00M |
| EBIT | -62.93M | -80.39M | -74.55M | -84.87M | -84.98M |
| EBITDA | -62.33M | -79.64M | -73.55M | -83.66M | -83.65M |
| EPS Basic | -0.32 | -0.43 | -0.41 | -0.46 | -0.45 |
| Normalized Basic EPS | -0.21 | -0.27 | -0.25 | -0.28 | -0.28 |
| EPS Diluted | -0.32 | -0.43 | -0.41 | -0.46 | -0.45 |
| Normalized Diluted EPS | -0.21 | -0.27 | -0.25 | -0.28 | -0.28 |
| Average Basic Shares Outstanding | 173.42M | 172.39M | 171.26M | 169.23M | 167.34M |
| Average Diluted Shares Outstanding | 173.42M | 172.39M | 171.26M | 169.23M | 167.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |